Send us Feedback

Alimera Sciences (ALIM)
Analysis
SUMMARY
BULLS
BEARS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
pSivida (PSDV) Affirms Availability of Iluvien in U.K. (ALIM)
StreetInsider.com  Apr 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/pSivida+%28PSDV%29+Affirms+Availability+of+Iluvien+in+U.K.+%28ALIM%29/8284290.html for the full story.
Alimera (ALIM) Announces Availability of Iluvien in the U.K.
StreetInsider.com  Apr 29  Comment 
Alimera Sciences, Inc. (ALIM) Posts Q4 Loss of 17c/Share
StreetInsider.com  Mar 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Alimera+Sciences%2C+Inc.+%28ALIM%29+Posts+Q4+Loss+of+17cShare/8204443.html for the full story.
Alimera Sciences (ALIM) Reports U.K. NICE Deems ILUVIEN Not Cost Effective as DME Treatment
StreetInsider.com  Jan 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Alimera+Sciences+%28ALIM%29+Reports+U.K.+NICE+Deems+ILUVIEN+Not+Cost+Effective+as+DME+Treatment/8024793.html for the full story.
Alimera (ALIM) Receives Marketing Approval for ILUVIEN in Spain
StreetInsider.com  Jan 17  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Alimera+%28ALIM%29+Receives+Marketing+Approval+for+ILUVIEN+in+Spain/8014268.html for the full story.
Unusual 11 Mid-Day Movers 12/14: (ALIM) (QUAD) (STXS) Higher; (LPTN) (ZQK) (CYTX) Lower
StreetInsider.com  Dec 14  Comment 
Alimera Sciences, Inc. (Nasdaq: ALIM) 29.8% HIGHER; presented at the Oppenheimer 23rd Annual Healthcare Conference, though that was on December 12th. Shares seeing some incredible volume back over the $1.50 level. About 245 thousand shares have...
UPDATE: Oppenheimer Reiterates Outperform Rating, Lowers PT on Alimera Sciences
Benzinga  Nov 30  Comment 
In a report published Friday, Oppenheimer reiterated its Outperform rating on Alimera Sciences (NASDAQ: ALIM), but lowered its price target from $5.00 to $3.00. Oppenheimer Holdings noted, “On 11/29, ALIM announced that the UK's National...
U.K.'s NICE Says Alimera's ILUVIEN Not Recommended for Treatment of Chronic Diabetic Macular Edema
Benzinga  Nov 30  Comment 
Alimera Sciences (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for...
Alimera Sciences (ALIM) Files 19.6M Common Shelf for Shareholders
StreetInsider.com  Nov 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Alimera+Sciences+%28ALIM%29+Files+19.6M+Common+Shelf+for+Shareholders/7888788.html for the full story.
Racemi Announces Addition of VP Finance
Cloud Computing  Nov 9  Comment 
Racemi, the moving company for the cloud, announced that Christian Nelson joins as vice president of finance bringing more than 15 years experience in finance and accounting. Most recently, he was senior director of finance and controller for...
Alimera Sciences, Inc. (ALIM) Tops Q3 Loss Views by 1c/Share
StreetInsider.com  Nov 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Alimera+Sciences%2C+Inc.+%28ALIM%29+Tops+Q3+Loss+Views+by+1cShare/7854617.html for the full story.




RELATED WIKI ARTICLES

Related Articles

more ▼WIKI ANALYSIS
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/c/ce/IPO.jpg': No such file or directory @ blob.c/OpenBlob/2480. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/c/ce/IPO.jpg/40px-IPO.jpg' @ convert.c/ConvertImageCommand/2800.
 This company completed an initial public offering (IPO) of its stock in 2010. View articles that reference this company.
Recent IPOs:   Globe Specialty Metals   •   LogMeIn   •   Invesco Mortgage Capital   •   Medidata   •   Chemspec
 
TOP CONTRIBUTORS
Sr. Director
Caleb Li

Alimera Sciences (ALIM) (NASDAQ:ALIM) is a pharmaceutical drug company focusing on ophthalmic diseases, which focuses around the area of the eye. It's best product candidate is Iluvien to treat diabetes patients that have a disease in their retina. Worldwide there are around 285 million diagnosed with diabetes. Thus, the company estimates 340,000 cases of this retinal disorder annually. The company does not expect to have any sales until the first quarter of 2011. [1]

The company faces risks from not being FDA approved in the three stage process. Furthermore, even if the drug is approved, the company has to market the product well. The product needs to be cost-effective and potential advantages over other products. [1]

The company's initial public offering of stock filed on the NASDAQ exchange on 2 November 2009. The proposed offer price range is $15.00-$17.00. The company is offering 6.0 million shares and raising $96 million. [1]

The company is pre-revenue with products coming to the market soon. [1]

References

  1. ↑ 1.0 1.1 1.2 1.3 Alimera Sciences S-1/A
Retrieved from "http://www.wikinvest.com/stock/Alimera_Sciences_(ALIM)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki